Back to Results
First PageMeta Content
Clinical pharmacology / Food and Drug Administration / Pharmacology / Therapeutics / United States Public Health Service / Center for Drug Evaluation and Research / B-cell chronic lymphocytic leukemia / Hematology / Brian Monahan / Medicine / Health / Pharmaceutical sciences


Minimal Residual Disease (MRD) as a Surrogate Endpoint in Chronic Lymphocytic Leukemia (CLL) Workshop Meeting Roster February 27, 2013 FDA White Oak Campus, Building 31, the Great Room, White Oak Conference Center
Add to Reading List

Open Document

File Size: 18,60 KB

Share Result on Facebook
UPDATE